Global DNA Sequencing Market to Reach $29.89 Billion by 2028 at a CAGR of 17.9% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global DNA Sequencing Market, By Product, By Application, By Technology, By End-User & By Region- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.
Global DNA Sequencing Market is valued at USD 5.1 Billion in 2021, and it is anticipated to attain a value of USD 29.89 Billion by 2028, at a CAGR of 17.9% over the prediction period (2022 - 2028).
Rapid advancements in bioinformatics and sequencing technology have made it possible to find DNA variations. These discoveries also reveal differences connected to a higher risk of illness. The widespread usage of Next-generation sequencing (NGS) and whole-genome sequencing (WGS), which enable several genes to be analysed concurrently on a single diagnostic platform, has boosted the effectiveness of DNA sequencing in clinical diagnostics applications. Personalised targeted sequencing of tumours accelerates the development of pharmacological therapies for cancer and identifies new cancer targets or pathways.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global DNA Sequencing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report
The Global DNA Sequencing Market is segmented based on Product, Application, Technology, End-User, and Region. Based on Product, it is categorized into Consumable, Instrument, Service. Based on Application, it is categorized into Biomarkers, Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Forensics, Others. Based on Technology, it is categorized into Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real-time Sequencing, Chain Termination Sequencing, Nanopore Sequencing. Based on End-User, it is categorized into Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals & Clinics. Based on the region it is categorized into: North America, Europe, Asia-Pacific, South America, and MEA.
Growing clinical symptoms are assumed to represent viral infections in recent years, but it is becoming more difficult to identify the virus that is causing them using standard culture procedures or molecular approaches. The discovery of new viruses has in the past been facilitated by the random sequencing of viral genomes. At the moment, these techniques are becoming more and more popular. The importance of DNA sequencing has grown as a result of its principal application in the detection of viruses.
To create a whole genome, the raw data produced by sequencing technologies must be combined. The computational challenges involved in processing this raw data are regarded to be the key barrier preventing the growth of the DNA sequencing market. The existence of repeating repeats makes it challenging to put the entire genome together. Such industry-wide issues have an effect on overall expansion.
High-throughput sequencing methods have seen a surge in demand in recent years. This method for next-generation DNA sequencing makes it possible to sequence hundreds of samples simultaneously and at a lower cost. DNA sequencing is frequently used to identify the patient's kind of cancer and helps the medical team give the patient a more effective course of treatment. NGS technology is more in demand as a result of COVID-19 since it helps track the virus's spread and gives guidance for potential future treatments.
- Agilent Technologies, Inc.(US)
- Thermo Fisher Scientific, Inc.(US)
- Illumina, Inc.(US)
- F. Hoffmann-La Roche Ltd.(Switzerland)
- Oxford Nanopore Technologies Ltd.(UK)
- Macrogen, Inc.(South Korea)
- Perkin Elmer, Inc.(US)
- Pacific Biosciences of California, Inc.(US)
- Bio-Rad Laboratories, Inc.(US)
- Myriad Genetics(US
For more information about this report visit https://www.researchandmarkets.com/r/c88an2
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900